"Anti-Bacterial Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit the growth or reproduction of BACTERIA.
| Descriptor ID |
D000900
|
| MeSH Number(s) |
D27.505.954.122.085
|
| Concept/Terms |
Anti-Bacterial Agents- Anti-Bacterial Agents
- Agents, Anti-Bacterial
- Anti Bacterial Agents
- Antibacterial Agents
- Agents, Antibacterial
- Anti-Bacterial Compounds
- Anti Bacterial Compounds
- Compounds, Anti-Bacterial
Anti-Mycobacterial Agents- Anti-Mycobacterial Agents
- Agents, Anti-Mycobacterial
- Anti Mycobacterial Agents
- Antimycobacterial Agents
- Agents, Antimycobacterial
|
Below are MeSH descriptors whose meaning is more general than "Anti-Bacterial Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Bacterial Agents".
This graph shows the total number of publications written about "Anti-Bacterial Agents" by people in this website by year, and whether "Anti-Bacterial Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 3 | 1 | 4 |
| 2012 | 8 | 0 | 8 |
| 2013 | 4 | 2 | 6 |
| 2014 | 9 | 0 | 9 |
| 2015 | 3 | 1 | 4 |
| 2016 | 8 | 2 | 10 |
| 2017 | 10 | 4 | 14 |
| 2018 | 5 | 1 | 6 |
| 2019 | 7 | 3 | 10 |
| 2020 | 6 | 6 | 12 |
| 2021 | 3 | 7 | 10 |
| 2022 | 4 | 5 | 9 |
| 2023 | 1 | 6 | 7 |
| 2024 | 9 | 4 | 13 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Bacterial Agents" by people in Profiles.
-
Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. Antimicrob Agents Chemother. 2025 Feb 13; 69(2):e0125124.
-
Pharmacokinetics of cefiderocol in a patient with carbapenem-resistant Acinetobacter baumannii ventriculitis: A?case report. Pharmacotherapy. 2025 Jan; 45(1):66-69.
-
Perioperative Antibiotic Use in Pediatric Solid Tumor Resection: A Two-center Retrospective Cohort Study. J Pediatr Surg. 2025 Feb; 60(2):162008.
-
Decolonization strategies for ESBL-producing or carbapenem-resistant Enterobacterales carriage: a systematic review and meta-analysis. Sci Rep. 2024 Oct 17; 14(1):24349.
-
Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible Staphylococcus aureus in patients from intensive care units in Colombia and use of a modified rapid nitrocefin test for detection. Antimicrob Agents Chemother. 2024 11 06; 68(11):e0089824.
-
A comprehensive study of catalytic pyrolysis of antibiotic fermentation residue over red mud-Ca(OH)2 composites. J Hazard Mater. 2024 Dec 05; 480:135772.
-
Metabolic disruption impairs ribosomal protein levels, resulting in enhanced aminoglycoside tolerance. Elife. 2024 Aug 02; 13.
-
In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2024 Sep; 38:252-255.
-
Mechanisms of gelofusine protection in an in vitro model of polymyxin B-associated renal injury. Am J Physiol Renal Physiol. 2024 Jul 01; 327(1):F137-F145.
-
Alternative iron-depleted media for cefiderocol susceptibility testing. Int J Antimicrob Agents. 2024 Jul; 64(1):107193.